The detection of mutated epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) with residual cell pellets derived from liquid-based cytology (LBC) samples (eg, endoscopic ultrasound-guided fine-needle aspiration) has been validated with allele-specific polymerase chain reaction. The aim of this study was to validate next-generation sequencing (NGS) technology for detecting gene mutations with residual cell pellets from LBC.
INTRODUCTION
Lung cancer continues to be a leading cause of cancer mortality in the United States for both men and women, with approximately 27% of all cancer deaths in the United States due to lung cancer. 1 Although there have been modest declines in the incidence of lung cancer in the past couple of decades, advances in survival have been relatively slow. 1 Recent advances in targeted therapies for patients with certain driver mutations have been promising.
In its guidelines (version 4.2016), the National Comprehensive Cancer Network recommends testing patients with non-small cell lung cancer (NSCLC) for genetic alterations that may have predictive or prognostic significance. 2 For example, NSCLC patients with activating epidermal growth factor receptor (EGFR) mutations are more likely to respond to tyrosine kinase inhibitors such as erlotinib, afatinib, and gefitinib. 3 Compared with patients receiving conventional chemotherapy, patients with actionable EGFR mutations who receive tyrosine kinase inhibitor therapies have longer progression-free survival and experience less toxicity. Currently, these therapies are limited to patients in whom molecular targets can be successfully detected by accredited clinical laboratories that perform these assays in accordance with federal guidelines and use either Food and Drug Administrationapproved assays or validated laboratory-developed tests. The detection of EGFR gene mutations of NSCLC on residual cell pellets derived from liquid-based cytology (LBC) samples has been validated with allele-specific polymerase chain reaction (PCR) at our institution 4 and has been reliably reproduced by others. [5] [6] [7] [8] [9] These fine-needle aspiration materials are stored in CytoLyt or PreservCyt fluid. In our experience, sufficient DNA extraction from residual PreservCyt samples has been shown even after the same specimen has been used to make a ThinPrep slide (Hologic, Marlborough, Mass) to detect gene rearrangements 10 and a cell block to perform immunohistochemical stains for confirmation of the tumor cell type. The advantages of adapting LBC for the molecular diagnosis of NSCLC include the reliable isolation of optimal-quality nucleic acids, 11, 12 the preservation of original cytology diagnostic slides, and the sparing of the cell block to allow for future testing. Therefore, at our institution, cytology samples obtained by needle techniques have been recommended as the first approach for the diagnosis and staging of suspected NSCLC, especially for those without distant metastases.
11
Next-generation sequencing (NGS) has become a widely accepted method for simultaneously interrogating multiple lung cancer-associated genes in NSCLC. 11, 13, 14 NGS has typically been validated on specimen types that sacrifice cytopathology slides or formalin-fixed, parffinembedded cell blocks. 15, 16 With the growing interest in performing molecular diagnostic testing with NGS, highquality genomic DNA as the starting material is the key to success. Previously, we have demonstrated the use of a realtime PCR assay in testing EGFR mutations with residual, concentrated cell pellet materials. 4 In this study, we have further evaluated the usefulness of genomic DNA extracted from tumor LBC specimens for NGS-based molecular oncology testing in an effort to further expedite NSCLC molecular testing.
MATERIALS AND METHODS

Ethics
This study was conducted as part of clinical laboratory test validation, and the Institutional Review Board of Cleveland Clinic waived the need for IRB approval and patient consent.
Tumor Samples
All specimens were collected from confirmed NSCLC patients. Tissue from lymph nodes was collected with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). 4, 17 The lung tumors were obtained by EBUS-TBNA, navigational bronchoscopyguided needle aspiration, or transthoracic needle aspiration. 4, 18, 19 The pleural fluid samples were obtained via a pleural tap through the chest wall. Twenty samples had DNA concentrations at or higher than 1 ng/mL, the concentration recommended by the manufacturer for building an NGS library. The DNA concentrations of the remaining 29 samples were below the 1 ng/mL cutoff. These specimens were originally collected in CytoLyt and were then centrifuged and preserved in PreservCyt fluid (Hologic). A cell pellet was prepared and used to make a ThinPrep slide and a Cellient cell block. The remainder of the cell pellet was used to extract genomic DNA for molecular testing.
DNA Extraction
The DNA extraction method was described in a previous publication. 4 Briefly, the PreservCyt specimens were manually extracted according with the Gentra Puregene DNA extraction kit (Qiagen, Hilden, Germany) according to the user's manual. The extracted genomic DNA was stored for the short term at 4 8C. We did not experience any issue of decreasing DNA quality in the storage period of 1 to 2 months. Thermo Fisher Scientific) was also used to confirm the validity of variants. The NextGENe viewer was used to visually inspect the quality of read alignment (pile-up) and variant calls, such as the presence of nucleotide homopolymer regions, the position of a variant, and the annotation of the sequencing results.
The quality score Q20 was applied when a given sequencing read was filtered; the regions of any 3 consecutive bases with a quality score less than Q20 were trimmed from that read. For a given sample, minimum coverage of 100 reads in genomic regions of interest was considered to be successful sequencing. With this quality control matrix, allelic fractions as low as 5% to 10% could be identified.
Sequencing Data Confirmation
Samples of known EGFR sequence changes, previously determined with the Therascreen EGFR RGQ PCR kit (Qiagen, Hilden, Germany), 20 a Food and Drug Administration-approved real-time PCR method, were used to validate the workflow for the AmpliSeq Cancer Hotspot Panel on the Ion Torrent PGM platform. Therascreen is able to detect common EGFR mutations such as T790M, L858R, L861Q, G719X, S768I, exon 19 deletions, and exon 20 insertions. The EGFR real-time PCR assay was performed as previously described, 4 Variants found in genes other than EGFR (eg, ERBB2, KRAS, MET, and PIK3CA) in the validation samples were further confirmed by resequencing of the genomic DNAs with the Illumina MiSeq instrument (unpublished data). Briefly, tumor genomic DNAs were extracted, and selected genomic regions were multiplex PCR-amplified with total input DNA at 10 ng (except for 1 sample at 5 ng). The Illumina TruSeq adaptors were ligated, and the prepared libraries were sequenced on MiSeq. 21 Minimum coverage of 100 reads in these selected genomic regions of interest was considered acceptable.
RESULTS
NGS of Positive-Control DNA
Commercially available genomic DNA (HD200; Horizon Diagnostics, Cambridge, United Kingdom) served as the positive control. This sample, which contained multiple hotspot mutations at defined allelic fractions, was used as the reference standard for the initial testing. Seven sequencing libraries using HD200 DNA were built, sequenced, and analyzed at different times. Each sequencing result reproducibly revealed the 6 engineered mutations in the NSCLC-related genes at allelic fractions (ranging from 6% to 25%) similar to those revealed by the manufacturer and with minimal variation in the means and standard errors of variant fractions. For example, the mutation fraction in PIK3CA p.E545K was 8.86% 6 0.46%, the mutation fraction in EGFR p.G719S was 24.14% 6 0.59%, and the mutation fraction in KRAS p.G13D was 15.0% 6 0.53%. The detailed mutation fractions, coverage depth, and 95% confidence intervals are shown in Table 1 . Hotspot mutations at allelic fractions of 4% or less, such as those resulting in EGFR L858R (manufacturer's listed allelic fraction, 3%) and T790M (manufacturer's listed allelic fraction, 1%) changes in the HD200 control, were not revealed because our analysis pipeline filters any variants below this fraction cutoff. In addition, filtering was placed for known single-nucleotide polymorphisms with coverage less than 4 reads and variants with less than 20 3 coverage depth. To minimize overcalling variants of low-level allelic fractions and nonspecific sequencing artifacts, variants at the homopolymer regions with forward/ reverse read ratios < 0.85 were also filtered.
Sequencing Archival LBC Samples
We selected 20 NSCLC LBC samples as a validation set to test the mutation status in 6 candidate genes with AmpliSeq Cancer Hotspot Panel v2.0 on the Ion Torrent PGM. All samples were assayed and analyzed in a blind fashion, with the previously determined EGFR mutation status remaining de-identified until all experiments were Original Article complete and variants were called. The tumor locations and percentages, identified sequence changes, coverage depths, and alternative confirmation methods are shown in Table 2 . All samples were multiplexed and sequenced to at least 100 3 coverage at all hotspot loci within the 6 candidate genes in each sample. Among them, only 1 sample (sample 26) had a less than 100 3 coverage area despite its average coverage of more than 8003. It is worth noting that this undercovered area is located at a GC-rich region within PIK3CA exon 1. In an effort to prepare NGS libraries from other specimen types (eg, formalin-fixed, paraffin-embedded tissue), this region may occasionally experience lower than expected coverage due to suboptimal multiplex PCR amplification.
A total of 12 EGFR mutations were identified in the validation set; they included 4 EGFR exon 19 deletions, 1 exon 20 insertion, and 7 missense changes. In addition, several common KRAS and BRAF mutations as well as 1 less common MET missense change and an ERBB2 insertion change were also found. These results show that our NGS data analysis pipeline is optimal with respect to sequence alignment and variant calling for revealing at least 15-base insertion-deletions (eg, sample 2) in the tumor DNA. The identified EGFR variants were fully concordant with the real-time PCR (Therascreen) results determined previously. For the validity of non-EGFR sequencing changes, we further examined them with an independent sequencing-by-synthesis NGS platform (MiSeq). We chose not to use Sanger sequencing-based methods for the confirmation because Sanger sequencing may not detect variants with allelic fractions less than 20%. All identified sequence changes were fully concordant with the variants determined by alternative methods.
Intrarun and Interrun Performance
To test the intrarun and interrun sequencing accuracy and reproducibility, 2 samples (samples 2 and 8 in Table 2 ) with relatively low allelic fractions of EGFR mutations were assayed (Table 3 ). The EGFR loci were sequenced deeply to reveal mutations at approximately 5% allelic fractions in NSCLC specimens. For the intrarun testing, these 2 samples were tested in triplicate in the same batch (library preparation, sequencing run, and data analysis). A 15-base exon 19 deletion (c.2240_2254delTAAGA-GAAGCAACAT) and an exon 21 missense mutation (c.2573T>G; p.858L>R) were revealed at average fractions of 5.5% and 9.4%, respectively. These data are consistent with the previously observed allelic burdens of 5% and 10%, respectively (Table 2) . No other sequence changes were identified in all mutation hotspots of the 6 NSCLC-related genes. Similarly, for the interrun testing, the aforementioned 2 samples were prepared, sequenced, and analyzed in triplicate in 3 different batches on 3 different days. The same pathogenic EGFR exon 19 deletion and exon 21 missense sequence changes were seen with average fractions of 4.9% and 11.3%, respectively; however, no other disease-causing mutations were identified in the 6 NSCLC-related genes.
Sequencing of Low-Quantity LBC Specimens
LBC is a different preparation type containing small yet valuable biological specimens for pathological examination.
Even a small LBC specimen obtained through this procedure may be sufficient for performing several downstream pathologic evaluations, including histological and molecular testing. 5,13,15,21-25 The manufacturer's AmpliSeq Cancer Hotspot Panel v2.0 NGS protocol suggests 10 ng of genomic DNA as the starting material. In our experience, the extraction of LBC specimens may occasionally produce less than the recommended amount of genomic DNA. To demonstrate that our NGS workflow may be applicable to suboptimal quantities of genomic DNA, we performed NGS testing on 29 LBC specimens with less than a 1 ng/mL genomic DNA concentration (or 10-ng total input), which represented all low-DNA concentration LBC NSCLC samples extracted and collected at our institution in 2015. As shown in Table 4 , most low-input DNA samples (n 5 18 [62%]) were successfully processed and sequenced, with the greatest success in the third and fourth quarters of 2015. We found that even in the 18 suboptimal samples, the mutation hotspots in the 6 NSCLC-related genes had sufficient coverage depth (more than the 100 3 minimum requirement) for confident scoring of the hotspot mutation status.
Eleven of the 29 prepared NGS libraries (38%) did not meet the quality control criteria (for details, see the Materials and Methods section). For these samples, no further NGS steps were performed, and the samples were denoted as QNS. Because the EGFR mutation status has direct therapeutic implications for NSCLC patients, we further investigated the use of Therascreen as a reflex test for interrogating EGFR mutation hotspots in those QNS samples. As shown in Table 4 , Therascreen was successfully performed and did not identify any EGFR hotspot mutation in the 11 QNS samples. Interestingly, in the samples with a less than 1 ng/lL DNA concentration, we noticed that the amount of total input genomic DNA did not predict the success of NGS library preparation. The performance of these low-DNA quantity samples is correlated with the timing of the sample preparation: better NGS results were obtained for those performed in the second half of 2015, and this suggests that there may have been other limiting factors that were improved over time in our laboratory.
DISCUSSION
We validated and implemented the use of genomic DNA extracted from residual cell pellets derived from NSCLC LBC specimens for NGS testing; in all, there were 273 such cases in 2015. Nearly 90% of these samples yielded extracted DNA that met the manufacturer's suggested parameters for NGS library preparation and sequencing. Approximately 10% of the LBC specimens were less cellular and resulted in lower DNA concentrations and quantities. Nonetheless, we found that in the majority of the cases in which a low quantity of DNA was extracted, an Ion AmpliSeq Cancer Hotspot library could still be successfully prepared and improved over the course of the year (Table 4) . Overall, our data demonstrate a robust NGS workflow for analyzing LBC specimens to generate accurate and reproducible sequencing results. For those DNA samples that were insufficient for NGS library preparation, which accounted for less than 4% of the total LBC specimens, a reflexive allele-specific, real-time PCR assay was able to determine the EGFR mutation hotspot status in a timely manner. Although this real-time PCR approach represents an alternative to NGS, its sensitivity varies among various hotspot targets. For example, the lowest reported levels of EGFR G719X and T790M mutations that are detectable by Therascreen are 5.43% and 7.02%, respectively. 20 In contrast, NGS with adequate reads may detect missense sequence changes at allelic fractions less than 5%, and this can be critically important in NSCLC patient management because it can inform therapy when scant specimens are obtained. For example, certain EGFR mutations such as T790M may indicate an acquired resistance to tyrosine kinase inhibitors. Knowledge of the exact mutation status, particularly at low fractions, will greatly influence an oncologist's therapeutic decision making.
There are several possibilities that may explain why certain DNA specimens were insufficient in preparing NGS libraries from LBC specimens. First, the device used to quantify genomic DNAs may not have accurately measured samples with very low concentrations. The Qubit fluorometer is most commonly used for double-stranded DNA quantification. The fluorometer's readings at 0.1 ng/lL or lower may be less accurate and subject to measurement variations that result in lower than expected DNA input during the library preparation. This may partially explain why the total input DNA amount did not correlate with the success of NGS library preparation. Second, laboratory process improvements may have improved NGS library preparation over time and reduced the number of QNS samples. We noticed that the majority of QNS DNAs occurred in the first 6 months of 2015 when the laboratory had just launched NGS testing. Throughout this time period, quality assurance and improvements in procedures, such as reducing the elution volume during the genomic DNA extraction, closely monitoring optical density (OD) ratios (260/280 and 260/230) of extracted DNA for sample triage, and implementing competency tests of technologist's bench skills in NGS preparation, were ongoing. It is worth mentioning that the discordance between the input DNA amount and the NGS performance may have been affected by the DNA quality, which was monitored with the aforementioned OD ratios. Although we have not performed a systematic investigation, the observed low 260/230 OD ratios in some extracted DNAs was linked to poor NGS library preparation when a suboptimal amount of DNA was used. A further improvement of the DNA extraction method may better indicate the DNA quality required for NGS preparation. Moreover, for the majority of the samples collected with EBUS-TBNA, our cytopathologists also began requesting 4-6 additional needle passes placed directly into Cytolyt after rendering a positive diagnosis. 26 A noticeable decrease in QNS cases during the second half of 2015 suggests that improvements in our laboratory operational procedures may have facilitated the processing of NGS specimens.
As for false-positive calls arising with low-input starting DNA, our laboratory takes this issue very seriously. During the assay validation stage, positive calls were always confirmed by another independent method. In general, sequence changes that had more than 100 3 coverage and a 10% allelic fraction, were within mutation hotspots, and were derived from libraries with robust amplification profiles were confirmed to be real. Nevertheless, false signals did occur in some NGS libraries made with a suboptimal amount of starting DNA. Typically, false signals may be associated with 1 or more of the following factors: 1) a poorly amplified NGS library, 2) insufficient coverage in the genomic regions of interests, 3) low allelic fractions of the identified variants, and 4) genomic regions other than mutation hotspots of the cancer. When a variant call belongs to the aforementioned categories, we do confirm the finding before reporting it to our clinician.
In summary, we have demonstrated a robust NGS workflow with the AmpliSeq Cancer Hotspot Panel and Ion Torrent PGM sequencer for examining LBC specimens from NSCLC patients. In the vast majority of the cases, we met the recommended minimal starting DNA content and determined the mutation hotspot status in a timely manner. 27 Several previously published studies of NGS of cytology specimens were conducted with DNA from cytology smears or formalin-fixed, paraffin-embedded cell blocks. 12, 28 Though bypassing the labor-and time-intensive steps of scraping cells from slides or deparaffinizing formalin-fixed, paraffin-embedded cell blocks, we have been able to improve the turnaround time and save precious diagnostic material. Our method of using concentrated cell pellets from LBC specimens for NGS testing is a method that improves the way of caring for lung cancer patients.
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